Overall, these data confirm that NAMPT plays a central role in phenotypic plasticity of melanoma and during the onset of resistance, suggesting a rational to target this enzyme in melanoma patients in combination with targeted- and immuno-therapy (Figure 2). The gene discussed is NAMPT; the disease is melanoma.